Harrow (HROW) Competitors

Harrow logo
$29.09 -1.03 (-3.42%)
Closing price 04:00 PM Eastern
Extended Trading
$29.08 -0.02 (-0.05%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HROW vs. ARQT, LQDA, OGN, TARS, and SUPN

Should you buy Harrow stock or one of its competitors? Harrow's main competitors and comparable companies include Arcutis Biotherapeutics (ARQT), Liquidia (LQDA), Organon & Co. (OGN), Tarsus Pharmaceuticals (TARS), and Supernus Pharmaceuticals (SUPN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Harrow compare to Arcutis Biotherapeutics?

Harrow (NASDAQ:HROW) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Harrow has higher earnings, but lower revenue than Arcutis Biotherapeutics. Harrow is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harrow$272.30M4.01-$5.14M-$0.78N/A
Arcutis Biotherapeutics$376.07M9.13-$16.14M$0.21129.29

In the previous week, Harrow had 23 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 29 mentions for Harrow and 6 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.75 beat Harrow's score of 0.37 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Harrow
5 Very Positive mention(s)
4 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arcutis Biotherapeutics
0 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Arcutis Biotherapeutics has a net margin of 5.88% compared to Harrow's net margin of -9.39%. Arcutis Biotherapeutics' return on equity of 14.18% beat Harrow's return on equity.

Company Net Margins Return on Equity Return on Assets
Harrow-9.39% -69.81% -5.16%
Arcutis Biotherapeutics 5.88%14.18%6.28%

Harrow has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

Harrow currently has a consensus target price of $66.20, indicating a potential upside of 127.57%. Arcutis Biotherapeutics has a consensus target price of $39.75, indicating a potential upside of 46.41%. Given Harrow's higher possible upside, analysts plainly believe Harrow is more favorable than Arcutis Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harrow
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.44
Arcutis Biotherapeutics
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80

72.8% of Harrow shares are owned by institutional investors. 12.8% of Harrow shares are owned by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Arcutis Biotherapeutics beats Harrow on 10 of the 15 factors compared between the two stocks.

How does Harrow compare to Liquidia?

Harrow (NASDAQ:HROW) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Harrow has a net margin of -9.39% compared to Liquidia's net margin of -15.15%. Liquidia's return on equity of 264.65% beat Harrow's return on equity.

Company Net Margins Return on Equity Return on Assets
Harrow-9.39% -69.81% -5.16%
Liquidia -15.15%264.65%44.19%

Harrow currently has a consensus price target of $66.20, indicating a potential upside of 127.57%. Liquidia has a consensus price target of $75.23, indicating a potential upside of 33.46%. Given Harrow's higher probable upside, analysts plainly believe Harrow is more favorable than Liquidia.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harrow
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.44
Liquidia
1 Sell rating(s)
5 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.50

Harrow has higher revenue and earnings than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than Harrow, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harrow$272.30M4.01-$5.14M-$0.78N/A
Liquidia$158.32M32.08-$68.92M-$1.23N/A

72.8% of Harrow shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 12.8% of Harrow shares are held by insiders. Comparatively, 25.6% of Liquidia shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Harrow has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

In the previous week, Liquidia had 6 more articles in the media than Harrow. MarketBeat recorded 35 mentions for Liquidia and 29 mentions for Harrow. Liquidia's average media sentiment score of 0.60 beat Harrow's score of 0.37 indicating that Liquidia is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Harrow
5 Very Positive mention(s)
4 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Liquidia
8 Very Positive mention(s)
5 Positive mention(s)
11 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Liquidia beats Harrow on 9 of the 16 factors compared between the two stocks.

How does Harrow compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Harrow (NASDAQ:HROW) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Organon & Co. has a net margin of 3.49% compared to Harrow's net margin of -9.39%. Organon & Co.'s return on equity of 82.06% beat Harrow's return on equity.

Company Net Margins Return on Equity Return on Assets
Organon & Co.3.49% 82.06% 6.03%
Harrow -9.39%-69.81%-5.16%

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 12.8% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Organon & Co. has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organon & Co.$6.22B0.59$187M$0.7618.30
Harrow$272.30M4.01-$5.14M-$0.78N/A

Organon & Co. has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, Harrow has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market.

Organon & Co. presently has a consensus price target of $12.00, indicating a potential downside of 13.70%. Harrow has a consensus price target of $66.20, indicating a potential upside of 127.57%. Given Harrow's stronger consensus rating and higher possible upside, analysts clearly believe Harrow is more favorable than Organon & Co..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organon & Co.
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
Harrow
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.44

In the previous week, Harrow had 25 more articles in the media than Organon & Co.. MarketBeat recorded 29 mentions for Harrow and 4 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.55 beat Harrow's score of 0.37 indicating that Organon & Co. is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Organon & Co.
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Harrow
5 Very Positive mention(s)
4 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Organon & Co. beats Harrow on 9 of the 15 factors compared between the two stocks.

How does Harrow compare to Tarsus Pharmaceuticals?

Harrow (NASDAQ:HROW) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

Harrow has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

72.8% of Harrow shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Harrow has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harrow$272.30M4.01-$5.14M-$0.78N/A
Tarsus Pharmaceuticals$451.36M8.60-$66.42M-$15.19N/A

In the previous week, Harrow had 28 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 29 mentions for Harrow and 1 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.79 beat Harrow's score of 0.37 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Harrow Neutral
Tarsus Pharmaceuticals Very Positive

Harrow presently has a consensus price target of $66.20, indicating a potential upside of 127.57%. Tarsus Pharmaceuticals has a consensus price target of $104.57, indicating a potential upside of 32.91%. Given Harrow's higher possible upside, equities research analysts plainly believe Harrow is more favorable than Tarsus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harrow
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.44
Tarsus Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

Harrow has a net margin of -9.39% compared to Tarsus Pharmaceuticals' net margin of -102.93%. Tarsus Pharmaceuticals' return on equity of -24.51% beat Harrow's return on equity.

Company Net Margins Return on Equity Return on Assets
Harrow-9.39% -69.81% -5.16%
Tarsus Pharmaceuticals -102.93%-24.51%-12.40%

Summary

Tarsus Pharmaceuticals beats Harrow on 9 of the 16 factors compared between the two stocks.

How does Harrow compare to Supernus Pharmaceuticals?

Harrow (NASDAQ:HROW) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

Harrow has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

72.8% of Harrow shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Comparatively, 0.7% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Supernus Pharmaceuticals has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harrow$272.30M4.01-$5.14M-$0.78N/A
Supernus Pharmaceuticals$1.24B2.75$210M$3.588.05

In the previous week, Harrow had 25 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 29 mentions for Harrow and 4 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.48 beat Harrow's score of 0.37 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Harrow
5 Very Positive mention(s)
4 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Supernus Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Harrow presently has a consensus price target of $66.20, indicating a potential upside of 127.57%. Supernus Pharmaceuticals has a consensus price target of $60.20, indicating a potential upside of 108.81%. Given Harrow's higher possible upside, equities research analysts plainly believe Harrow is more favorable than Supernus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harrow
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.44
Supernus Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.71

Supernus Pharmaceuticals has a net margin of 32.75% compared to Harrow's net margin of -9.39%. Harrow's return on equity of -69.81% beat Supernus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Harrow-9.39% -69.81% -5.16%
Supernus Pharmaceuticals 32.75%-418.04%42.96%

Summary

Supernus Pharmaceuticals beats Harrow on 9 of the 16 factors compared between the two stocks.

Get Harrow News Delivered to You Automatically

Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HROW vs. The Competition

MetricHarrowPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.06B$13.75B$7.85B$12.17B
Dividend YieldN/A2.58%2.46%4.41%
P/E RatioN/A26.0432.9627.39
Price / Sales4.017.318.595.73
Price / Cash32.7415.7421.9322.50
Price / Book37.785.144.403.70
Net Income-$5.14M$2.88B$3.52B$392.17M
7 Day Performance5.90%-3.87%-5.34%-4.53%
1 Month Performance6.63%-3.96%-3.61%-5.86%
1 Year Performance-28.68%-7.13%0.01%-7.78%

Harrow Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HROW
Harrow
2.8655 of 5 stars
$29.09
-3.4%
$66.20
+127.6%
-26.2%$1.06B$272.30MN/A373
ARQT
Arcutis Biotherapeutics
4.1781 of 5 stars
$26.20
+2.5%
$39.75
+51.7%
+13.0%$4.28B$376.07M162.14354
LQDA
Liquidia
3.3254 of 5 stars
$47.87
+7.8%
$72.85
+52.2%
+104.7%$4.24B$158.32M34.58216
OGN
Organon & Co.
1.5135 of 5 stars
$13.86
-0.1%
$11.40
-17.7%
+84.2%$3.63B$6.22B18.2310,000
TARS
Tarsus Pharmaceuticals
3.3891 of 5 stars
$70.84
+3.3%
$104.57
+47.6%
+10.1%$3.41B$451.36MN/A370

Related Companies and Tools


This page (NASDAQ:HROW) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners